Drug Profile
Research programme: antibody therapeutics - Curia/XOMA
Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator LakePharma; XOMA
- Developer XOMA
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 14 Feb 2022 LakePharma has been acquired and merged into Curia
- 28 Nov 2021 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 04 Oct 2017 XOMA Corporation enters into a non-exclusive license agreements with LakePharma for use of its proprietary phage display libraries for antibody discovery and development